ArticleClinical epidemiology2026
Continued Use of Medications Withdrawn Internationally for Safety Concerns: Insights from an Urban Employed Population in China.
Article in Clinical epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Some drugs approved for marketing are later withdrawn in other countries due to safety concerns. This study aimed to examine the use of such drugs in China and explore factors associated with continued prescribing. Methods: A 5% random sample of the Urban Employee Basic Medical Insurance (UEBMI) database (2019-2021) from a province in China was used. Withdrawn drugs were identified from two global databases, the Onakpoya dataset and the WITHDRAWN 2.0 database that included withdrawals from 1950 to 2020. Generalized linear mixed models incorporating hospital random effects were applied, adjusting for individual-level covariates (age, sex, ethnicity, occupation, and supplementary public servant medical benefits) and institution-level covariates (medical institution level, hospital ownership and type, and region of treatment). Results: We included 293,859 insured individuals, of whom 16,510 (5.62%) received at least one withdrawn drug. Thirty-eight such drugs were prescribed, 26 of which remained available without restriction in China. Overall use declined from 6.21% in 2019 to 5.46% in 2021. Mean per-person spending on withdrawn drugs declined from 402.88 yuan in 2019 to 258.36 yuan in 2021. The reductions in usage and spending were mainly observed in inpatient prescribing. Nervous system medications were most frequently used (27.3% of outpatient and 52.2% of inpatient uses) and accounted for the largest share of expenditures (40.3%). Greater use was observed among men, retirees, and those with supplementary public servant medical benefits, as well as in tertiary, private, and general hospitals. Conclusion: Drugs withdrawn internationally for safety concerns continued to be prescribed in China, despite overall declines in use. Efforts to strengthen post-marketing surveillance, improve alignment between domestic regulatory actions and global safety evidence, and enhance prescribing oversight-particularly in higher-level hospitals-may help reduce avoidable patient exposure to unsafe medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.